ERBB2 and breast carcinoma: As per the results of a pooled analysis of 6377 patients with primary breast cancer receiving neoadjuvant chemotherapy (reported by von Minckwitz et al. [24]), the pCR rate for HER2-positive patients who did not receive trastuzumab was 23.3%, and that for those who received trastuzumab was 40.9%.